LABORATORY FOR THE PROPHYLACTIC PENICILLIN STUDY II

本合同的目标是：1)通过以下方式识别干扰 青霉素预防葡萄球菌抗体的获得 肺炎；2)评估青霉素耐药葡萄球菌的出现。 肺炎；3)青霉素预防停药后，比较 记录在案的该患者的细菌感染发生率 有儿童接受青霉素治疗的人群；4)确定 5岁以上持续青霉素预防干预 与加强免疫的血清抗体反应 肺炎球菌疫苗或随后开发的天然 肺炎链球菌血清抗体；5)检测，儿童 肺炎链球菌感染，如果他们有可检测到的血清 对感染血清型的抗体；以及6)确定患者是否 患严重肺炎球菌感染的人血清水平较低 肺炎链球菌感染或应答前的抗体滴度 与肺炎球菌疫苗相比，这是次优的 未感染的患者。

The objectives of this contract are to 1) identify interference by penicillin prophylaxis on the acquisition of antibodies to S. pneumoniae; 2) assess the emergence of penicillin resistant S. pneumoniae; 3) upon cessation of penicillin prophylaxis, compare the incidence of documented bacterial infection in that patient population with children receiving penicillin; 4) to determine if continued penicillin prophylaxis beyond 5 years of age interferes with the serum antibody response to booster immunization with the pneumococcal vaccine or subsequent development of natural serum antibodies to S. pneumoniae; 5) to determine, in children with S. pneumoniae infection, if they had detectable serum antibody to the infecting serotype; and 6) to determine if patients who develop severe pneumococcal infection have lower serum antibody titers to S. pneumoniae before infection or respond suboptimally to the pneumococcal vaccine as compared to patients without infection.